Risk-Benefit Analysis and Personalized Treatment in Multiple Sclerosis: Basing Treatment Goals on the Latest Evidence

This live meeting took place on June 1, 2018. 

An enduring clinical supplement of the live meeting content will be available with an upcoming issue of the International Journal of MS Care
 later in 2018.

A CME/CE-certified Symposium in conjunction with the 2018 Annual Meeting of the CMSC

Friday, June 1, 2018
Breakfast and Registration: 6:30-7:00am (Breakfast courtesy of CMSC)
CME/CE Program: 7:00-8:00am

Nashville Music City Center
Nashville, TN
Karl F. Dean Grand Ballroom A, Level 4

 Patricia K. Coyle, MD, FAAN, FANA
 Professor and Vice Chair (Clinical Affairs), Department of Neurology
 Director, MS Comprehensive Care Center
 Stony Brook University Medical Center
 Stony Brook, NY


 Clyde E. Markowitz, MD
 Director, MS Center
 Associate Professor of Neurology
 Perelman School of Medicine, University of Pennsylvania
 Philadelphia, PA


In the last decade, there have been significant advances in the treatment of multiple sclerosis (MS) and newer disease-modifying therapies (DMTs) can provide control of disease activity in many patients, especially when more aggressive treatment is started early in appropriate patients. There is good evidence to support the new treatment outcome of “no evidence of disease activity” (NEDA) based on an absence of relapses, no sustained progression on EDSS disability score, and no new or enlarging lesions on MRI.

With more than a dozen approved first-line therapies, initial treatment selection can be complicated by risk/benefit, efficacy, and long- and short-term safety profiles. There are evidence-based benefits with aggressive, early treatment regimens, so clinicians must make the optimal initial treatment choice. Risk-Benefit Analysis and Personalized Treatment in Multiple Sclerosis: Basing Treatment Goals on the Latest Evidence will provide participants with the most up-to-date evidence on current and emerging MS therapies and treatment goals, as well as treatment strategies to achieve those goals.


Welcome and Introductions
Analyzing the Evidence to Achieve New Treatment Goals in MS
Evaluating Current Safety/Efficacy Data of DMTs for MS
Balancing Benefits vs Risks: Information for Patients and Physicians
Q&A Session and Activity Roundup

This activity is intended for MS specialists, neurologists, nurses, and other healthcare professionals who manage patients with MS.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Describe the benefits of starting an optimal DMT early to achieve the new treatment goal of “no evidence of disease activity” (NEDA)
  • Evaluate the short- and long-term safety, tolerability, immunologic profiles, and efficacy of available DMTs for MS
  • Apply knowledge of the benefits and risks of available DMTs to select an optimal personalized MS treatment

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Rockpointe.  CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physicians – This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Nurses – The CMSC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Physicians–The Potomac Center for Medical Education designates this live activity for a maximum of 1.00 AMA PRA Category I CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit, the post-test, or evaluation, please email contact@potomacme.org.

Nurses – The CMSC designates this activity for 1.0 credit of continuing nursing education (1.0 credits are in the area of pharmacology). For information about the nursing accreditation of this program, please contact the CMSC at education@mscare.org.

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME/CE certificate will be emailed within 2 weeks upon submission of a completed evaluation form.

There are no fees associated with this program.

Event staff will be glad to assist you with any specials needs (e.g. physical, dietary, etc.).  Please email specialservices@rockpointe-pcme.com  at least 5 days prior to the program.


Jointly provided by the Potomac Center for Medical Education, the Consortium of Multiple Sclerosis Centers, and Rockpointe


This program is supported by educational grants from Biogen, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.